2-Chlor-4-(N-Methylpiperazino)-chinazolin | 39216-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-Chlor-4-(N-Methylpiperazino)-chinazolin
• 英文别名: 2-chloro-4-(4-methylpiperazin-1-yl)quinazoline；2-chloro-4-(4-methylpiperazinyl)quinazoline
• CAS: 39216-68-7
• 化学式: C₁₃H₁₅ClN₄
• mdl: MFCD09726547
• 分子量: 262.742
• InChiKey: LZCJDDILEMCNLD-UHFFFAOYSA-N

物化性质

• 沸点：
  380.7±42.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Chlor-4-(N-Methylpiperazino)-chinazolin 在 吡啶 、 氨 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 5.0h， 生成 2-[[4-(4-Methylpiperazin-1-yl)quinazolin-2-yl]amino]benzamide
  参考文献：
  名称：

  部分喹唑啉和喹唑啉-4-氧代喹唑啉衍生物的合成及抗炎筛选

  摘要：

  描述了 2-芳基-4-氧代-1-(4-喹唑基)喹唑啉的一些新衍生物的合成。N-（4-喹唑基）邻氨基苯甲酸甲酯与异（硫）氰酸苯酯反应生成3-苯基-1-（4-喹唑基）-1、2、3、4-四氢-2、4-二氧-和4-氧代-2-硫代喹唑啉（分别为3a和3b） 或者，邻氨基苯甲酰胺衍生物与芳香醛环化得到2-芳基-4-氧代-1-（4-喹唑基）-1, 2, 3 , 4-四氢喹唑啉 5. 另一方面，2-氯-4-（4-取代的1-哌嗪基）喹唑啉衍生物在2-位进行相同类型的反应，分别得到相应的喹唑啉衍生物8和10 . 此外，酰胺4b与酰氯环化得到相应的2-芳基-1-（2-氯-4-喹唑基）-4-氧代-1，4-二氢喹唑啉 11 从中合成三唑并喹唑啉衍生物 13 和 15 通过中间体肼衍生物 112 大多数新合成的化合物都经过了抗炎活性的测试。然而，发现一些新化合物表现出良好的抗炎效力。

  DOI：

  10.1002/ardp.200290009
• 作为产物：
  描述：

  2,4-喹唑啉二酮 在 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 乙酸乙酯 为溶剂， 反应 4.5h， 生成 2-Chlor-4-(N-Methylpiperazino)-chinazolin
  参考文献：
  名称：

  Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics

  摘要：

  The histamine H-4 receptor is a G protein-coupled receptor that has attracted much interest for its role in inflammatory and immunomodulatory functions. In our search for new H4R ligands, a low affinity isoquinoline fragment was optimized to 7-(furan-2-yl)-4-(piperazin-1-yl)quinazolin-2-amine (VUF11489), as a new H4R antagonist. Analysis of its binding kinetics at the human H4R showed this compound to have a very different dissociative half-life in comparison with reference antagonist JNJ7777120. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.104

文献信息

• Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
  申请人：Caprathe William Bradley

  公开号：US20050096327A1

  公开（公告）日：2005-05-05

  This invention relates to compounds of the formula 1 wherein R 1 , R 2 , and R 3 and R 4 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

  这项发明涉及公式1的化合物 其中R 1 ，R 2 ，R 3 和R 4 如规范中所定义，包含它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。
• 2,4-Diaminoquinazolines as antithrombotic agents
  申请人：Eli Lilly and Company

  公开号：US03956495A1

  公开（公告）日：1976-05-11

  2,4-diaminoquinazolines are employed as antithrombotic agents and have the following general formula: ##SPC1## Wherein R.sub.1 and R.sub.2 are monovalent groups independently selected from the group consisting of ##EQU1## wherein R.sub.4 and R.sub.5 independently are selected from the group consisting of hydrogen, alkyl, and cycloalkyl, with the proviso that both R.sub.4 and R.sub.5 cannot be cycloalkyl, ##EQU2## wherein R.sub.6, R.sub.7, and R.sub.8 independently are selected from the group consisting of hydrogen and alkyl, and A is a divalent organic group having from two to about six carbon atoms such that the two nitrogen atoms are separated by at least two carbon atoms, and C. heterocyclic-amino, and R.sub.3 is a monovalent group selected from the group consisting of hydrogen, halogen, and alkyl.

  2,4-二氨基喹唑啉被用作抗血栓药物，具有以下一般公式：其中R.sub.1和R.sub.2是从以下组成的单价基团中独立选择的：其中R.sub.4和R.sub.5独立地选自氢、烷基和环烷基组成的组，但R.sub.4和R.sub.5不能同时为环烷基；其中R.sub.6、R.sub.7和R.sub.8独立地选自氢和烷基组成的组，A是一个具有两到约六个碳原子的双价有机基团，使得两个氮原子至少被两个碳原子分隔，并且C.杂环氨基，R.sub.3是从氢、卤素和烷基组成的单价基团中选择的。
• AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE
  申请人：Morimoto Hiroshi

  公开号：US20110166135A1

  公开（公告）日：2011-07-07

  The present invention provides aromatic nitrogen-containing 6-membered ring compounds having excellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I 0 ] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I 0 ] wherein: X 1 , X 2 and X 3 each independently are N or CH, and at least two of X 1 , X 2 and X 3 are N; A is *—CH═CH—, *—C(Alk)=CH—, *—CH 2 —CH 2 — or *—O—CH 2 — (* is a bond with R 1 ); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R 1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y 0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) —O—R 2 wherein R 2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y 0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R 1 is not quinoxalinyl or quinolyl.

  本发明提供了具有优异的PDE10抑制活性的芳香族含氮6元环化合物。本发明涉及以下式[I0]或其药学上可接受的盐，其为一种芳香族含氮6元环化合物，以及其制备方法，用于PDE10抑制剂的化合物和包含该化合物作为活性成分的药物组合物：式[I0]其中：X1、X2和X3各自独立地为N或CH，且至少两个X1、X2和X3为N；A为*—CH═CH—、*—C(Alk)=CH—、*—CH2—CH2—或*—O—CH2—（*为R1的键）；Alk为低碳基；环B为可选取代的含氮脂肪族杂环基；R1为可选取代的含氮杂环基，其中含氮杂环基是从喹啉基、喹啉基、异喹啉基、喹唑啉基、吡嗪基、嘧啶基和它们与5至6元脂环环融合的基中选择的基；Y0为从以下组合中选择的基（1）到（5）：（1）可选取代的苯基或可选取代的芳香单环5至6元杂环基；（2）可选取代的氨基甲酰基；（3）可选取代的氨基低碳基；（4）—O—R2，其中R2为氢、可选取代的低碳基、低环烷基、脂肪单环5至6元杂环基或式[AA]；（5）单取代或双取代的氨基；但当Y0为单取代或双取代的氨基时，R1的含氮杂环基不是喹啉基或喹啉基。
• Synthesis and bioactivities of novel piperidylpyrimidine derivatives: inhibitors of tumor necrosis factor-alpha production
  作者：Norio Fujiwara、Hitoshi Fujita、Kiyotaka Iwai、Ayumu Kurimoto、Shinobu Murata、Hajime Kawakami

  DOI：10.1016/s0960-894x(00)00227-4

  日期：2000.6

  New piperidylpyrimidine derivatives, including quinazolines, were prepared, and their abilities to inhibit TNF-alpha production evaluated. Some compounds showed potent inhibitory activity in mouse macrophages stimulated with LPS. The synthesis and structure-activity relationships of these compounds are described. (C) 2000 Elsevier Science Ltd. All rights reserved.
• Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics
  作者：Rogier A. Smits、Herman D. Lim、Tiffany van der Meer、Sebastiaan Kuhne、Karin Bessembinder、Obbe P. Zuiderveld、Maikel Wijtmans、Iwan J.P. de Esch、Rob Leurs

  DOI：10.1016/j.bmcl.2011.10.104

  日期：2012.1

  The histamine H-4 receptor is a G protein-coupled receptor that has attracted much interest for its role in inflammatory and immunomodulatory functions. In our search for new H4R ligands, a low affinity isoquinoline fragment was optimized to 7-(furan-2-yl)-4-(piperazin-1-yl)quinazolin-2-amine (VUF11489), as a new H4R antagonist. Analysis of its binding kinetics at the human H4R showed this compound to have a very different dissociative half-life in comparison with reference antagonist JNJ7777120. (C) 2011 Elsevier Ltd. All rights reserved.